411
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:September 30, 2022Completed
Stage III Multiple Myeloma: 436 Clinical Trials, Page 42 of 44
Hide Studies Not Open or Pending
412
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
Condition(s):Smoldering Multiple MyelomaLast Updated:May 31, 2023Active, not recruiting
413
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
Condition(s):Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary ComplicationsLast Updated:November 7, 2018Completed
414
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Condition(s):Lymphoma; Multiple MyelomaLast Updated:June 1, 2022Completed
415
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
Condition(s):Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol SpecificLast Updated:February 15, 2013Completed
416
A Study of Real Life Treatment for Multiple Myeloma (MM)
Condition(s):Multiple MyelomaLast Updated:February 8, 2023Recruiting
417
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Condition(s):Plasma Cell MyelomaLast Updated:June 1, 2023Recruiting
418
STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS
Condition(s):Multiple MyelomaLast Updated:March 25, 2022Active, not recruiting
419
Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)
Condition(s):Multiple MyelomaLast Updated:October 7, 2015Completed
420
Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:May 23, 2022Completed